Wouter Willems

机构：Johnson & Johnson (United States), Janssen (Belgium), Johnson & Johnson (Netherlands), Johnson & Johnson (Brazil) · ORCID：0009-0006-5831-3749

发表论文 35 篇 · 总被引 806 次 · h-index 16

代表论文

• Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial (2020 · The Lancet Infectious Diseases · 被引 172)
• Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial (2024 · The Lancet Infectious Diseases · 被引 41)
• OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA (2013 · Annals of the Rheumatic Diseases · 被引 23)
• Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases (2024 · Nature Communications · 被引 20)
• Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults (2023 · Clinical Infectious Diseases · 被引 18)
• Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries (2021 · Trials · 被引 18)